Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. Patients received low-dose conditionin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Locke, Frederick L., Neelapu, Sattva S., Bartlett, Nancy L., Siddiqi, Tanya, Chavez, Julio C., Hosing, Chitra M., Ghobadi, Armin, Budde, Lihua E., Bot, Adrian, Rossi, John M., Jiang, Yizhou, Xue, Allen X., Elias, Meg, Aycock, Jeff, Wiezorek, Jeff, Go, William Y.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363293/
https://ncbi.nlm.nih.gov/pubmed/28129122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2016.10.020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados